Money
Filter News
Found 84,846 articles
-
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly.
-
On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, Intra-Cellular Therapies is now offering 6.8 million shares at $73 a piece.
-
23andMe announces CEO’s intention to pursue a potential take-private
4/18/2024
23andMe Holding Co., a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission.
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
4/18/2024
Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
-
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
4/18/2024
Zura Bio Limited today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”).
-
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
4/18/2024
RenovoRx, Inc. announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC that the Company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550.
-
Precision Optics Announces Receipt of $720,000 Follow-On Production Order from Top Tier Defense/Aerospace Customer for New Optical Application
4/18/2024
Precision Optics Corporation, Inc. announced it has received a $720,000 follow on production order from a top tier defense/aerospace company addressing a commercial application that leverages the Company's proprietary manufacturing technology developed for high precision micro-optics systems.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
4/18/2024
NRx Pharmaceuticals, Inc. announced that has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550 and has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter.
-
Soligenix Announces Pricing of $4.75 Million Public Offering
4/18/2024
Soligenix, Inc. announced the pricing of its public offering of 11,875,000 shares of common stock and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses.
-
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
4/18/2024
NRx Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses.
-
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/18/2024
Bio-Path Holdings, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules.
-
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
4/18/2024
Longeveron Inc. announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024.
-
Intuitive Announces First Quarter Earnings 2024
4/18/2024
Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended March 31, 2024.
-
Korro Announces $70 Million Private Placement
4/18/2024
Korro Bio, Inc. announced that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses.
-
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
4/18/2024
Sensus Healthcare, Inc. announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024.
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
4/18/2024
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
-
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
4/18/2024
Sight Sciences, Inc. announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024.
-
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
4/18/2024
TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 18, 2024
4/18/2024
Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
4/18/2024
Biohaven Ltd. announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.